Hem › Njurcancer (renalcelskarcinom) › Florida › Jacksonville
Kliniska studier för Njurcancer (renalcelskarcinom) i Jacksonville, FL
14 studier för Njurcancer (renalcelskarcinom) söker deltagare vid platser i och runt Jacksonville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RekryterarFas 2
- Mayo Clinic in Florida, Jacksonville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekryterarFas 1
- Mayo Clinic Florida, Jacksonville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekryterarFas 1
- Exelixis Clinical Site #78, Jacksonville
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RekryterarFas 2
- Mayo Clinic in Florida, Jacksonville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekryterarObservationsstudie
- Mayo Clinic Jacksonville, Jacksonville
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekryterarFas 2
- Mayo Clinic in Florida, Jacksonville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekryterarFas 1/2
- Mayo Clinic Pharmacy, Jacksonville
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
RekryterarFas 1/2
- Mayo Clinic in Florida, Jacksonville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekryterarFas 1
- Xencor Investigative Site, Jacksonville
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RekryterarFas 1/2
- Mayo Clinic Jacksonville, Jacksonville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekryterarFas 1
- Mayo Clinic Comprehensive Cancer Center, Jacksonville
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RekryterarObservationsstudie
- Mayo Clinic in Florida, Jacksonville
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekryterarFas 1/2
- Mayo Clinic, Jacksonville
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RekryterarFas 1/2
- Mayo Clinic in Florida, Jacksonville
Njurcancer (renalcelskarcinom)-studier i andra städer
- Houston, TX35 studier
- New York City, NY27 studier
- Dallas, TX23 studier
- Nashville, TN23 studier
- St. Louis, MO23 studier
- Los Angeles, CA20 studier
- Boston, MA16 studier
- Baldwin Park, CA16 studier
- Pittsburgh, PA15 studier
- Philadelphia, PA15 studier
- Queens, NY15 studier
- Cleveland, OH14 studier
Andra studier i Jacksonville
- Bröstcancer40 studier
- Icke-småcellig lungcancer39 studier
- Cancer (alla typer)29 studier
- Metastaserande cancer28 studier
- Kolorektal cancer27 studier
- Prostatacancer26 studier
- Övervikt25 studier
- Hjärtsvikt21 studier
- Bukspottkörtelcancer20 studier
- Övervikt19 studier
- Multipelt myelom18 studier
- Lungcancer17 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.